Ivan Cheung – Chairman, Eisai Inc.; President, Neurology Business Group, Eisai Co., Ltd.

Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung also compares the differing challenges of the oncology and neuroscience markets and outlines the unique Eisai company culture.  
We have learned that to perform well in the US, we need to have a consistently robust pipeline instead of relying on just one or two blockbusters
Become a PharmaBoardroom Member for free to access this content
Join the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report